Clinical Trials Browser

Terminated × Leukemia, Myeloid, Acute × IL32 protein, human × Clear all

NCT01106950 2017-12-28

Haploidentical Natural Killer Cells to Treat Refractory or Relapsed Acute Myelogenous Leukemia (AML)

Phase 2 Terminated

15 enrolled 12 charts

Other hematologic neoplasm

Leukemia, Myeloid, Acute